Malignant Ovarian Serous Tumor — Trials

Malignant Ovarian Serous Tumor — Trials · CancerIndex

Clinical trials

Registered studies

154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 69
Recruiting: 29
Ph III recruiting: 4
Growth YoY: —
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 51–56 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02627430	Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer	withdrawn	Phase 1	0	National Cancer Institute (NCI)NIH	0	Jul 26, 2016	clinicaltrials
NCT02470559	Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent	withdrawn	Phase 1	0	Barbara Ann Karmanos Cancer InstituteOTHER